Researchers from Osaka University in Japan have discovered a way to convert human pluripotent stem cells into ...Read more
Ironwood Pharmaceuticals, Inc., a US based commercial biotechnology company, has announced that the National M...Read more
InVivo Therapeutics Holdings Corp, a research and clinical-stage biomaterials and biotechnology company with a...Read more
Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces that is ha...Read more
Health 4.0 boosts Asia MedTech, Bio-pharma in 2019
Asia is a region of stark contrasts, with approximately 4.5 billion people – some 60 per cent of the world’s population – living in countries with a rich diversity of economic, political, and demographic constituents. In the coming year Asia will become a major hub for MedTech and Bio-Pharma activities for both local as well multinational companies.
Biotech companies in the region are also actively partnering with leading global biopharmaceutical companies on both the R&D and commercial fronts. Asset-level partnership remains very active during 2019. According to McKinsey Asia has the potential to leapfrog in the digital-health segment. Asia has an opportunity to take the lead in developing big data/advanced analytics solutions and technology platforms, with the potential to contribute to the global healthcare ecosystem.